A Phase II Study of Flutamide in Ovarian Cancer

Overview

Journal Oncology

Specialty Oncology

Date 1997 May 1

PMID 9143399

Citations 15

Authors

M Vassilomanolakis

G Koumakis

V Barbounis

H Hajichristou

S Tsousis

A Efremidis

Affiliations

Soon will be listed here.

Abstract

A phase II study of flutamide was conducted in 24 patients with stage III and IV ovarian cancer who failed chemotherapy and who had measurable disease. Flutamide was administered at a dose of 100 mg three times daily continuously until evidence of progression. Partial response observed in 1 of the 23 evaluable patients (4.3%) lasted 3 months. Two patients had stable disease (8.7%) for 7 and 8 months. The remaining 20 patients had progression of disease within 3 months. Toxicity was mild.

Citing Articles

Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol.

van der Ploeg P, Hendrikse C, Thijs A, Westgeest H, Smedts H, Caroline Vos M Heliyon. 2024; 10(1):e23170.

PMID: 38187310 PMC: 10770441. DOI: 10.1016/j.heliyon.2023.e23170.

Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.

Manning-Geist B, Gordhandas S, Giri D, Iasonos A, Zhou Q, Girshman J Gynecol Oncol. 2021; 164(1):12-17.

PMID: 34763937 PMC: 9449573. DOI: 10.1016/j.ygyno.2021.10.087.

Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications (Review).

Li H, Liu Y, Wang Y, Zhao X, Qi X Oncol Rep. 2021; 46(4).

PMID: 34435651 PMC: 8424487. DOI: 10.3892/or.2021.8174.

Androgen/Androgen Receptor Signaling in Ovarian Cancer: Molecular Regulation and Therapeutic Potentials.

Chung W, Chen L, Chang W, Su S, Hung Y, Ma W Int J Mol Sci. 2021; 22(14).

PMID: 34299364 PMC: 8304547. DOI: 10.3390/ijms22147748.

Fallopian Tube-Derived Tumor Cells Induce Testosterone Secretion from the Ovary, Increasing Epithelial Proliferation and Invasion.

Colina J, Zink K, Eliadis K, Salehi R, Gargus E, Wagner S Cancers (Basel). 2021; 13(8).

PMID: 33923536 PMC: 8073317. DOI: 10.3390/cancers13081925.